Literature DB >> 15466412

T-cell activation leads to poor activation of the HIV-1 clade E long terminal repeat and weak association of nuclear factor-kappaB and NFAT with its enhancer region.

Anne-Marie Lemieux1, Marie-Eve Paré, Brigitte Audet, Eric Legault, Sylvain Lefort, Nancy Boucher, Sébastien Landry, Tim van Opijnen, Ben Berkhout, Mojgan H Naghavi, Michel J Tremblay, Benoit Barbeau.   

Abstract

The enhancer region in the human immunodeficiency virus type 1 (HIV-1) 5'-long terminal repeat (LTR) is very important for viral transcription. This promoter sequence binds both nuclear factor-kappaB and NFAT, two important modulators of HIV-1 gene expression. Previous studies have indicated that the enhancer regions of the different HIV-1 clade LTRs differ in their number of NF-kappaB-binding sites. In this study, we have compared the activation potential of the different HIV-1 clade and HIV-2 LTRs and assessed their interaction with NFAT and NF-kappaB. In T-cell lines and primary CD4(+) T-cells, the results showed that the HIV-1 clade E LTR (with a single NF-kappaB-binding site) was the weakest LTR regardless of the tested activators, whereas the HIV-2 LTR was the most responsive LTR. The clade E enhancer region was also demonstrated to be the weakest enhancer region in transfection experiments with luciferase reporter-based vectors. Electrophoretic mobility shift assays with extracts from activated CD4(+) T-cells indicated that, although NF-kappaB and NFAT bound all enhancers, HIV-1 clade E and HIV-2 LTR enhancers were poor binding targets for these two factors. Weak NFAT binding to clade E enhancers was also confirmed using NFAT1-expressing 293T cells in competition experiments. We have also shown the absence of interaction of NF-kappaB or NFAT with the third NF-kappaB repeat present in clade C. However, the clade C enhancer bound NFAT more efficiently than all other enhancer regions tested. Our results hence demonstrate for the first time that differences in the binding of NF-kappaB and NFAT to the enhancer regions could be responsible for some of the observed variation in HIV-1 clade LTR activation, whereas HIV-2 LTR activation seems mostly independent of these interactions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466412     DOI: 10.1074/jbc.M409896200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Functional Incompatibility between the Generic NF-κB Motif and a Subtype-Specific Sp1III Element Drives the Formation of the HIV-1 Subtype C Viral Promoter.

Authors:  Anjali Verma; Pavithra Rajagopalan; Rishikesh Lotke; Rebu Varghese; Deepak Selvam; Tapas K Kundu; Udaykumar Ranga
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

2.  FOXP3 inhibits HIV-1 infection of CD4 T-cells via inhibition of LTR transcriptional activity.

Authors:  Nithianandan Selliah; Mingce Zhang; Sara White; Philip Zoltick; Bassel E Sawaya; Terri H Finkel; Randy Q Cron
Journal:  Virology       Date:  2008-10-01       Impact factor: 3.616

3.  IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer.

Authors:  Marco Sgarbanti; Anna L Remoli; Giulia Marsili; Barbara Ridolfi; Alessandra Borsetti; Edvige Perrotti; Roberto Orsatti; Ramona Ilari; Leonardo Sernicola; Emilia Stellacci; Barbara Ensoli; Angela Battistini
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

4.  Galectin-1 interacts with the human endogenous retroviral envelope protein syncytin-2 and potentiates trophoblast fusion in humans.

Authors:  Caroline Toudic; Amandine Vargas; Yong Xiao; Guillaume St-Pierre; Norbert Bannert; Julie Lafond; Éric Rassart; Sachiko Sato; Benoit Barbeau
Journal:  FASEB J       Date:  2019-09-07       Impact factor: 5.191

5.  Multiple NF-κB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance.

Authors:  Mahesh Bachu; Swarupa Yalla; Mangaiarkarasi Asokan; Anjali Verma; Ujjwal Neogi; Shilpee Sharma; Rajesh V Murali; Anil Babu Mukthey; Raghavendra Bhatt; Snehajyoti Chatterjee; Roshan Elizabeth Rajan; Narayana Cheedarla; Venkat S Yadavalli; Anita Mahadevan; Susarla K Shankar; Nirmala Rajagopalan; Anita Shet; Shanmugam Saravanan; Pachamuthu Balakrishnan; Suniti Solomon; Madhu Vajpayee; Kadappa Shivappa Satish; Tapas K Kundu; Kuan-Teh Jeang; Udaykumar Ranga
Journal:  J Biol Chem       Date:  2012-11-06       Impact factor: 5.157

6.  Induction of chromosomally integrated HIV-1 LTR requires RBF-2 (USF/TFII-I) and Ras/MAPK signaling.

Authors:  Tom Malcolm; Jiguo Chen; Carol Chang; Ivan Sadowski
Journal:  Virus Genes       Date:  2007-06-02       Impact factor: 2.332

7.  Identification of new splice sites used for generation of rev transcripts in human immunodeficiency virus type 1 subtype C primary isolates.

Authors:  Elena Delgado; Cristina Carrera; Paloma Nebreda; Aurora Fernández-García; Milagros Pinilla; Valentina García; Lucía Pérez-Álvarez; Michael M Thomson
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

8.  NFAT5 regulates HIV-1 in primary monocytes via a highly conserved long terminal repeat site.

Authors:  Shahin Ranjbar; Alla V Tsytsykova; Sang-Kyung Lee; Ricardo Rajsbaum; James V Falvo; Judy Lieberman; Premlata Shankar; Anne E Goldfeld
Journal:  PLoS Pathog       Date:  2006-12       Impact factor: 6.823

9.  An additional NF-κB site allows HIV-1 subtype C to evade restriction by nuclear PYHIN proteins.

Authors:  Matteo Bosso; Christina M Stürzel; Dorota Kmiec; Smitha Srinivasachar Badarinarayan; Elisabeth Braun; Jumpei Ito; Kei Sato; Beatrice H Hahn; Konstantin M J Sparrer; Daniel Sauter; Frank Kirchhoff
Journal:  Cell Rep       Date:  2021-09-21       Impact factor: 9.423

10.  Induction of galectin-1 expression by HTLV-I Tax and its impact on HTLV-I infectivity.

Authors:  Sonia Gauthier; Isabelle Pelletier; Michel Ouellet; Amandine Vargas; Michel J Tremblay; Sachiko Sato; Benoit Barbeau
Journal:  Retrovirology       Date:  2008-11-25       Impact factor: 4.602

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.